Lumen Press Releases

Back to News

5/17/2023 Lumen Bioscience Receives Fast Track Designation from U.S. FDA for LMN-201
5/10/2023 Lumen Bioscience Awarded $8.1 million from U.S. Department of Defense to Develop Fast-Acting, Intranasal Countermeasure Against Respiratory Viruses
1/5/2023 Lumen Bioscience Details 2022 Company and Facilities Growth, New Funding, and Clinical Pipeline Progress
1/4/2023 Lumen Bioscience Receives Broad Funding Support for Advancement of Antibiotic Alternative for Preventing Traveler’s Diarrhea
12/23/2022 Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections
12/20/2022 BARDA-funded Intranasal Antibody Cocktail for COVID-19 Shows Promise in a Preclinical Study
10/4/2022 Lumen Bioscience Announces Publication in NPJ Vaccines of Preclinical Data Demonstrating Needle Free, Spirulina-produced Vaccination Offering Protection Against Malaria
4/19/2022 KYORIN and Lumen Bioscience Reach Collaboration Research Agreement
4/15/2022 Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection
3/21/2022 Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins
12/22/2021 Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection
11/3/2021 Lumen Bioscience Partners with Leading Animal Health Company to Develop Oral Biologic Drugs and Reduce Antibiotic Use on Farms